
Novartis exec sold off shares before Zolgensma data scandal was revealed
pharmafile | August 19, 2019 | News story | Sales and Marketing | AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA made the public aware that data had been manipulated in trials of Zolgensma.
As revealed in a Swiss stock exchange filing from 19 July, a member of Novartis’ board of directors sold shares on the Swiss stock exchange less than three weeks before the FDA published a press release warning the public of faults in the data used for the approval of $2.1 million gene therapy Zolgensma on 6 August.
Novartis notified the FDA of faults in the data in June. The firm had first learned of the manipulation in March and had completed an internal investigation by early May. Shares in Novartis fell by as much as 3% on announcement of the news in early August.
Speaking to Reuters a spokesperson for Novartis said: “As is usual in such cases, the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …






